Eli Lilly (LLY)
(Real Time Quote from BATS)
$760.92 USD
-1.74 (-0.23%)
Updated Mar 19, 2024 09:50 AM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Eli Lilly and Company falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 34,124 | 28,541 | 28,318 | 24,540 | 22,320 |
Cost Of Goods | 7,082 | 6,630 | 7,313 | 5,483 | 4,721 |
Gross Profit | 27,042 | 21,912 | 21,006 | 19,057 | 17,598 |
Selling & Adminstrative & Depr. & Amort Expenses | 20,584 | 14,784 | 14,649 | 12,999 | 12,624 |
Income After Depreciation & Amortization | 6,458 | 7,127 | 6,357 | 6,058 | 4,974 |
Non-Operating Income | 97 | -321 | -202 | 1,172 | 292 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 6,555 | 6,806 | 6,156 | 7,230 | 5,266 |
Income Taxes | 1,314 | 562 | 574 | 1,036 | 628 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 5,240 | 6,245 | 5,582 | 6,194 | 4,638 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 3,681 |
Net Income (GAAP) | 5,240 | 6,245 | 5,582 | 6,194 | 8,318 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 7,985 | 8,650 | 7,905 | 7,382 | 6,207 |
Depreciation & Amortization (Cash Flow) | 1,527 | 1,523 | 1,548 | 1,324 | 1,233 |
Income After Depreciation & Amortization | 6,458 | 7,127 | 6,357 | 6,058 | 4,974 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 903.28 | 904.62 | 911.68 | 912.51 | 935.68 |
Diluted EPS Before Non-Recurring Items | 6.32 | 7.94 | 8.16 | 7.93 | 6.04 |
Diluted Net EPS (GAAP) | 5.80 | 6.90 | 6.12 | 6.79 | 8.89 |
Fiscal Year end for Eli Lilly and Company falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | 9,353.40 | 9,498.60 | 8,312.10 | 6,960.00 | 7,301.80 |
Cost Of Goods | 1,788.00 | 1,860.10 | 1,807.40 | 1,626.70 | 1,548.10 |
Gross Profit | 7,565.40 | 7,638.50 | 6,504.70 | 5,333.30 | 5,753.70 |
SG&A, R&D, and Dept/Amort Expenses | 5,109.90 | 7,188.10 | 4,379.00 | 3,839.30 | 3,917.30 |
Income After SG&A, R&D, and Dept/Amort Expenses | 2,455.50 | 450.40 | 2,125.70 | 1,494.00 | 1,836.40 |
Non-Operating Income | 121.00 | -23.20 | -36.80 | 35.70 | 260.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 2,508.80 | 427.20 | 2,088.90 | 1,529.70 | 2,096.40 |
Income Taxes | 319.10 | 484.60 | 325.70 | 184.80 | 158.70 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 2,189.70 | -57.40 | 1,763.20 | 1,344.90 | 1,937.70 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 2,189.70 | -57.40 | 1,763.20 | 1,344.90 | 1,937.70 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | 903.98 | 899.84 | 902.70 | 903.28 | 904.73 |
Diluted EPS Before Non-Recurring Items | 2.49 | 0.10 | 2.11 | 1.62 | 2.09 |
Diluted Net EPS (GAAP) | 2.42 | -0.06 | 1.95 | 1.49 | 2.14 |